ClinicalTrials.gg
Not yet recruitingNCT07945873PROP-LTUpdated Nov 18, 2026

Primary Sclerosing Cholangitis After Liver Transplant With Oral Vancomycin

A Phase 1 interventional study of Oral Vancomycin in Primary Sclerosing Cholangitis and Liver Transplant Disorder, sponsored by Yael R. Nobel. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Yael R. Nobel · Phase 1, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 76 studies in Cholangitis, Sclerosing with a site in United States — 20 open to participants now, 23 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Planned enrollment
34th of 58
21 · median 27
Started
2026
with 4 others
Phase 1
20 of 76
6 open now
Primary completion
2027-11
later than 8 of 22 live
Registered
76th of 76
by date

Among the 76 studies in Cholangitis, Sclerosing with a site in United States, this one is the 34th largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 8 of the 22 other live ones, and was the 76th registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

20 of the 76 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

  • To evaluate safety of a 4-week course of oral vancomycin (250 mg 3 times daily [TID]) in liver transplant recipients who were transplanted for Primary Sclerosing Cholangitis (PSC).

Secondary Objectives:

  • To determine tolerability and adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC.
  • To assess vancomycin resistant enterococcus (VRE) colonization status over time.
  • To assess the impact of oral vancomycin on stool microbiome composition, diversity, and function.
  • To assess impact of oral vancomycin on microbial metabolite concentrations in blood and stool.
  • To assess impact of oral vancomycin on liver-related biochemical markers.
Read the detailed description

Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts, often associated with inflammatory bowel disease (IBD). A subset of patients ultimately require liver transplantation, yet rPSC occurs in approximately 25-30% of transplant recipients and can lead to graft failure and re-transplantation.

There is increasing evidence that the gut microbiome plays a role in PSC and rPSC pathogenesis. Altered microbiota composition has been identified in patients with PSC. This association is true not only in patients with PSC compared to controls, but also in patients with PSC-IBD compared to patients with IBD-no PSC, indicating a true association with the liver disease itself. Compared to patients with PSC who do not develop post-transplant recurrence, patients who will develop rPSC have altered microbiome composition at the time of liver transplant. Microbial manipulation-including oral antibiotics, fecal microbiota transplantation, and other strategies-has emerged as a potential therapeutic avenue in native liver PSC. In particular, there is mounting interest in oral vancomycin (OV) as a treatment for PSC, as several case reports/case series and a few small trials have demonstrated that OV is associated with reductions in alkaline phosphatase and other markers of liver injury. This effect may be mediated by the impact of OV on bile acid metabolism, short-chain fatty acid production, and/or prevalence of specific bacterial taxa such as Enterococcus gallinarum, a vancomycin-sensitive microbe that has been associated with PSC.

In case reports of patients with post-transplant rPSC, use of OV was also associated with improvement in biochemical markers of liver disease activity. Liver transplant recipients represent a specialized population with unique medication exposures and microbiome composition. While short course of OV are safely used in liver transplant recipients for the treatment of Clostridioides difficile, no prospective study has systematically examined safety, tolerability, microbiome changes, and hepatic effects of OV in liver transplant recipients transplanted for PSC.

03

Conditions studied

  • Primary Sclerosing Cholangitis
  • Liver Transplant Disorder

Keywords

  • PSC
  • liver transplant
  • liver transplanted
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Ability to provide written, .
  • History of orthotopic liver transplantation within 1 to 10 years prior to enrollment (i.e. study drug initiation)
  • Diagnosis of PSC as the underlying liver disease leading to liver transplantation, based on compatible imaging findings (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiogram [PTC]), liver histology, and/or clinician judgment
  • Subjects with or without IBD may be enrolled. IBD diagnosis with a minimum disease duration of 6 months as assessed by endoscopy/histology. IBD should be in clinical remission or mildly active according to accepted clinical scores and/or clinician judgment.
  • Stable liver graft function, as determined by ALL of the following criteria:

    • No episodes of acute rejection within 6 months prior to enrollment, based on liver histology and/or clinical signs or symptoms
    • No episodes of cholangitis within 6 months prior to study enrollment, based on positive bacterial cultures, compatible imaging, and/or clinical signs or symptoms
    • No intervention for biliary obstruction (e.g. ERCP, PTC, surgical intervention) within 6 months prior to study enrollment.
    • Stable liver biochemistries within 6 months prior to study enrollment, as determined by: ALP \<5x
    • Absence of histologic or imaging findings suggestive of cirrhosis

Exclusion criteria

Exclusion Criteria:

  • History of colon resection at any time prior to study enrollment or presence of ileal/colonic diversion within 12 months prior to study enrollment
  • Documented VRE infection within 12 months prior to study enrollment
  • Documented C. difficile infection within 3 months prior to study enrollment
  • Systemic antibiotic exposure within 3 months prior to study enrollment
  • Change in any transplant or IBD-related or its dosing within 30 days prior to study enrollment
  • Currently taking oral vancomycin
  • Allergy or intolerance to vancomycin
  • Treatment with any drug within 3 months prior to study enrollment
  • Severe renal dysfunction ( \<30 mL/min/1.73 m²) or on dialysis
  • Any active
  • Pregnant or breastfeeding Page 8
  • Any condition that, in the investigator's judgment, would make participation unsafe or interfere with adherence (e.g., severe frailty, uncontrolled psychiatric disease, inability to adhere to TID dosing)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Study Arm - Oral Vancomycin

    Patients in study arm will be assigned to receive study drug.

    Drug: Oral Vancomycin

  • No intervention
    Control Arm - No Drug

    Patients in control arm will be assigned to receive no drug.

Interventions

  • DrugOral Vancomycin

    Vancomycin 250 mg orally three times per day (TID, 750 mg/day), with doses spaced approximately 8 hours apart (e.g., morning, midday, evening), for a total duration of 4 weeks. Missed doses will not be made up; participants will be instructed to resume the next scheduled dose. Vancomycin is a glycopeptide antibiotic supplied as oral capsules 250 mg. It acts by inhibiting bacterial cell wall synthesis. Oral vancomycin is minimally absorbed in patients with intact gut mucosa, resulting in high intraluminal concentrations.

    Also known as: VANCOCIN®, vancomycin hydrochloride

06

What researchers measure

Primary outcomes

  1. Proportion of patients experiencing any treatment-related adverse event of grade ≥2

    This is to evaluate safety of a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The assessments will be using CTCAE v6.0 grading in the study arm receiving vancomycin compared to the control arm. Percentage (or the number) of study participants who experience related AEs of grade \> or = 2 will be tallied and calculated.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Change in patient-reported short form-36 symptom questionnaire score

    To determine tolerability to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The clinical outcomes will be recorded using the SF-36 questionnaire. SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. Items are scored 0-100 with higher scores indicating a more favorable health state.

    Time frame: Baseline to 4 weeks, baseline to 8 weeks

  2. Proportion of participants who complete 4 weeks of oral vancomycin with ≥ 80% of planned doses

    To determine adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The completion of study treatment will be defined, assessed and tallied by self-report and/or pill count.

    Time frame: Up to 4 weeks

  3. Proportion of participants with VRE Colonization Status

    The status will be determined by the presence or absence of vancomycin-resistant Enterococcus (VRE) colonization based on stool sample or rectal swab testing. The result will be positive or negative. The participants with positive results will be tallied.

    Time frame: Baseline, Week 4, and Week 8

  4. Proportion of participants with changes in Stool Microbiome Composition and Diversity

    Proportion of participants with change in microbiome composition from baseline to subsequent timepoints as assessed by alpha and beta diversity, differential taxa abundance, and/or changes in genes and gene pathways.

    Time frame: Baseline to 4 weeks, Baseline to 8 weeks

  5. Proportion of participants with change in liver-related biochemical markers

    Participants with change in ALP, ALT, and/or GGT (particularly a decrease in ALP) will be tallied and calculated.

    Time frame: Baseline and 4 weeks, Baseline and 8 weeks

  6. Proportion of participants with change in microbial metabolite concentrations.

    Participants with changes in microbial metabolite such as short chain fatty acids and bile acids will be tallied and calculated.

    Time frame: Baseline and 4 weeks, Baseline and 8 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Bowlus CL, Arrive L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702. doi: 10.1002/hep.32771. Epub 2022 Oct 20. No abstract available. PubMed 36083140 ↗
  • Bogatic D, Bryant RV, Lynch KD, Costello SP. Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2023 Jan;57(1):23-36. doi: 10.1111/apt.17251. Epub 2022 Nov 2. PubMed 36324251 ↗
  • Hole MJ, Jorgensen KK, Holm K, Braadland PR, Meyer-Myklestad MH, Medhus AW, Reikvam DH, Gotz A, Grzyb K, Boberg KM, Karlsen TH, Kummen M, Hov JR. A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation. Hepatology. 2023 Mar 1;77(3):715-728. doi: 10.1002/hep.32773. Epub 2023 Feb 17. PubMed 36056902 ↗
  • Quraishi MN, Sergeant M, Kay G, Iqbal T, Chan J, Constantinidou C, Trivedi P, Ferguson J, Adams DH, Pallen M, Hirschfield GM. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut. 2017 Feb;66(2):386-388. doi: 10.1136/gutjnl-2016-311915. Epub 2016 Apr 19. No abstract available. PubMed 27196590 ↗
  • Visseren T, Fuhler GM, Erler NS, Nossent YRA, Metselaar HJ, IJzermans JNM, Darwish Murad S, Peppelenbosch MP. Recurrence of primary sclerosing cholangitis after liver transplantation is associated with specific changes in the gut microbiome pretransplant - a pilot study. Transpl Int. 2020 Nov;33(11):1424-1436. doi: 10.1111/tri.13692. Epub 2020 Jul 26. PubMed 33617049 ↗
  • Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):61-7. doi: 10.1097/MPG.0b013e31816fee95. PubMed 18607270 ↗
  • Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, Nadeau KC, Cox KL. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2013 Feb;33(2):397-406. doi: 10.1007/s10875-012-9801-1. Epub 2012 Oct 9. PubMed 23054338 ↗
  • Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013 Mar;37(6):604-12. doi: 10.1111/apt.12232. Epub 2013 Feb 5. PubMed 23384404 ↗
  • Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study. J Gastrointestin Liver Dis. 2016 Dec;25(4):457-464. doi: 10.15403/jgld.2014.1121.254.rah. PubMed 27981301 ↗
  • Ali AH, Damman J, Shah SB, Davies Y, Hurwitz M, Stephen M, Lemos LM, Carey EJ, Lindor KD, Buness CW, Alrabadi L, Berquist WE, Cox KL. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol. 2020 Aug;55(8):941-950. doi: 10.1080/00365521.2020.1787501. Epub 2020 Jul 7. PubMed 32633158 ↗
  • Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N, Yamaguchi A, Kanamori M, Kamada N, Hattori M, Ashida H, Sakamoto M, Atarashi K, Narushima S, Yoshimura A, Honda K, Sato T, Kanai T. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019 Mar;4(3):492-503. doi: 10.1038/s41564-018-0333-1. Epub 2019 Jan 14. PubMed 30643240 ↗
  • Davies YK, Tsay CJ, Caccamo DV, Cox KM, Castillo RO, Cox KL. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep Transplant. 2013;2013:314292. doi: 10.1155/2013/314292. Epub 2013 Feb 24. PubMed 23509657 ↗
  • Hey P, Lokan J, Johnson P, Gow P. Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. BMJ Case Rep. 2017 Sep 25;2017:bcr2017221165. doi: 10.1136/bcr-2017-221165. PubMed 28951512 ↗
  • Annavajhala MK, Gomez-Simmonds A, Macesic N, Sullivan SB, Kress A, Khan SD, Giddins MJ, Stump S, Kim GI, Narain R, Verna EC, Uhlemann AC. Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation. Nat Commun. 2019 Oct 17;10(1):4715. doi: 10.1038/s41467-019-12633-4. PubMed 31624266 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945873
Lead sponsor
Yael R. Nobel
Responsible party
Yael R. Nobel (Assistant Professor of Medicine Center for Liver Disease and Transplantation Division of Digestive and Liver Diseases Columbia University Medical Center, Columbia University) — Sponsor-investigator
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Rebecca Yeh, BA
Contact
ry2334@cumc.columbia.edu
2123053839
Thresiamma (Theresa) Lukose, PharmD
Contact
tt2103@cumc.columbia.edu
2123053839
Yael R Nobel, M.D., M.S.
principal investigator · Assistant Professor of Medicine Center for Liver Disease and Transplantation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion